STAT+: Pharmalittle: We’re reading about RSV vax link to GSB, a Pfizer donation, and more
And so, another working week will soon draw to a close. Not a moment too…
Category: Pharma
Despite good data, Ironwood’s shares plummet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?
WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American…
The next act for a biotech rainmaker
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more
Top of the morning to you, and a fine one it is. Cold winds and…
STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials
As pharma companies wrestle with how and when to use wearables and other digital technologies…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk
LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a…
STAT+: White House to hold a listening session on reforming pharmacy benefit managers
In a bid to combat prescription drug costs, the White House will hold a listening…
Beam is trading like it’s 2021
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about the FTC vs. PBMs, FDA adcomm voting and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: FTC says pharmacy benefit managers are stonewalling requests for information
A much-anticipated inquiry by U.S. antitrust regulators into pharmaceutical industry middlemen has been stymied because…
.jpg)
STAT+: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
GSK pill works in uncomplicated gonorrhea
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The FDA isn’t afraid to yank a disappointing drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Obesity treatment from Boehringer Ingelheim, Zealand Pharma succeeds in study in liver condition MASH
LONDON — A drug in development as a weight loss treatment succeeded in a Phase…
STAT+: Liver disease MASH is next target for obesity drugs in development
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy…
STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional
In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a…
STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription…
STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more
And so, another working week will soon draw to a close. Not a moment too…
What do CEOs owe the world?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA gives a mixed response to a petition seeking greater clinical trial transparency
The U.S. Food and Drug Administration told an advocacy group that it is not planning…
.jpg)
Novavax’s money is going in the wrong direction
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about India-made versions of Wegovy, an RSV vaccine scramble, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Novavax and Gavi end a bitter dispute over Covid-19 vaccines with a refund up to $400 million
After a contentious dispute, Novavax has agreed to refund up to $400 million to the…
STAT+: Pharmalittle: We’re reading about a CEO change at AbbVie, a long-acting HIV drug, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Actually Wegovy is good for dialysis companies, dialysis provider says
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AbbVie CEO Gonzalez to step down after a decade fiercely defending its top seller, Humira
AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it…
Bayer, short on cash, reaches into shareholders’ pockets
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more
Good morning, everyone, and welcome to another working week, which is getting off to a…
STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived
A U.S. appeals court revived a controversial lawsuit brought by nearly two dozen people who…
STAT+: Pharmalittle: We’re reading about kids taking Wegovy, telehealth for abortion pills, and more
And so, another working week will soon draw to a close. Not a moment too…
Alnylam thickened the plot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Hospital claims it was ‘drastically’ overcharged by pharma in a federal drug discount program
For several years, some of the world’s largest pharmaceutical companies that participate in a U.S….
Pharma’s contractors might finally be on the rebound
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a FTC probe into GPOs, a frostbite drug, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Leaked version of EFTA-India free trade deal sparks alarm over access to medicines
A leaked version of a proposed agreement between India and the European Free Trade Association…
STAT+: FTC to probe the role of middlemen in worsening drug shortage crisis
The Federal Trade Commission is launching a probe into the extent to which group purchasing…
STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Replicate’s srRNA rabies vaccine effective in Phase 1
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: STAT+: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira
It’s been one year since the launch of the first adalimumab biosimilar for Humira in…
The need to know biotech news stories today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more
Rise and shine, everyone, another busy day is on the way. However, the pace this…
Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate…
Was Pfizer’s “Here’s to Science” commercial during the Super Bowl a winning play or a fumble?
Super Bowl ads are a show within the show, an opportunity for brands and advertising…
Psychedelic investment continues to ramp up
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages
Aurobindo, which is one of the largest generic drug makers, has halted some production at…
Does Moderna’s RSV vaccine lose efficacy faster than others?
Want to stay on top of the science and politics driving biotech today? Sign up to get…